OPTN ELISA Kits
Optineurin (OPTN) is a multifunctional protein implicated in various cellular processes, including vesicular trafficking, autophagy, and the regulation of immune responses. Mutations in the OPTN gene have been associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and certain forms of glaucoma.
Available OPTN ELISA Kits:
- Human OPTN ELISA Kit by antibodies-online
- Features: Designed for the quantitative detection of OPTN in human samples, including cell lysates and tissue homogenates.
- Detection Range: 0.156–10 ng/mL
- Sensitivity: 0.061 ng/mL
- Applications: Suitable for research involving human OPTN expression and its role in disease mechanisms.
- Human Optineurin (OPTN) ELISA Kit by Biomatik
- Features: Utilizes a double-antibody sandwich format for detecting OPTN in tissue homogenates, cell lysates, and other biological fluids.
- Detection Range: 0.156–10 ng/mL
- Sensitivity: 0.061 ng/mL
- Applications: Applicable in studies focusing on ophthalmology and neurodegenerative diseases.
- Human OPTN (Optineurin) ELISA Kit by MyBioSource
- Features: Employs a sandwich enzyme immunoassay technique for the detection of OPTN in various human sample types.
- Detection Range: 0.156–10 ng/mL
- Sensitivity: <0.094 ng/mL
- Applications: Useful for quantifying OPTN levels in research related to immune response and neurodegeneration.
Applications of OPTN ELISA Kits:
- Disease Research: Investigating the involvement of OPTN in neurodegenerative diseases like ALS and glaucoma.
- Cell Biology: Studying OPTN's role in autophagy, vesicular trafficking, and immune response regulation.
- Drug Development: Assessing the impact of therapeutic agents targeting OPTN-related pathways.
When selecting an OPTN ELISA kit, consider factors such as sample type compatibility, sensitivity, detection range, and the specific requirements of your research. Consulting the manufacturer's datasheet and technical support can provide additional guidance to ensure optimal results.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|